header("Access-Control-Allow-Origin: *"); ?>
therapeuticpublished patents
oncologypublished patents
research tools
diagnosticpublished patents
Welcome to our Technology Offers website You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.
Diagnostic
Research
Therapeutic
Flow Cytometry
Immunocytochemistry
Immunoprecipitation
In vivo studies
Western Blot
Cardiovascular Diseases
Central Nervous System
Dermatology
Ear nose throat disease
Gastrointestinal Diseases
Genetic Disorders
Genito Urinary System
Hematological Disorders
Immunology
Musculoskeletal
Nutritional disorder
Oncology
Ophtalmology
Respiratory Disease
Women health
Others
Infectious diseases
Immune checkpoint blockade therapy is based on the inhibition of the tumor-mediated suppression of anticancer immune responses. However, the efficacy […]
The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the […]
The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates […]
The invention relates to melanoma antigen named MELOE and their use for preventing, treating and diagnosing melanoma. […]
The present invention relates to N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenylsulfonamide compounds which are useful as inhibitors of protein kinases, […]
Here, in multi-scale analyses using single-cell RNA sequencing of six different primary uveal melanomas, inventors uncover a previously unrecognized […]
The present invention relates to a method and composition for treating melanoma. More particularly, inventors have shown that high expression of USP14 […]
The present invention relates to a method for treating a subject suffering from melanoma resistant by administering to said subject an inhibitor of […]
Here the inventors show, using in vivo imaging and viral approaches, that calcium released by […]
In the present invention it is shown that the inactivation of the Pyk2 gene does not alter […]
In the present invention it is shows that the inactivation of the Pyk2 gene does not alter […]
The present invention relates to a method for treating a subject suffering from a cancer comprising […]
HSP110 is involved in multiple tumorigenic processes, but no inhibitor was known to date. The […]
The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no […]
Anthracyclines such as doxorubicin are chemotherapeutic molecules are also widely incorporated in […]
The present invention relates to methods and pharmaceutical compositions for the treatment of […]
Heart failure with preserved ejection fraction (HFpEF) which results from diastolic dysfunction is a […]
Inventors have surprisingly found that Emricasan is a much more potent inhibitor of monocyte […]
The present invention relates to a genetically modified hematopoietic stem cell (HSC) comprising, […]
The growing prevalence of obesity and type 2 diabetes complicates risk and clinical management by […]
Research tool licensing team
researchtools@inserm-transfert.fr
User accounts are momentarily unavailable
The Inserm Transfert website is currently undergoing maintenance. It will be available again in a few hours.